Last updated: January 25, 2026
Executive Summary
This report provides a comprehensive review of the litigation between Novo Nordisk Inc. and Mylan Institutional LLC, centered on patent infringement claims involving insulin products. Filed in 2019, the case (1:19-cv-01551) explores patent validity, infringement, and potential market implications. The case’s progression highlights key legal strategies, patent defenses, and settlement considerations influencing the insulin market and pharmaceutical patent enforcement.
Case Overview
| Aspect |
Details |
| Case Name |
Novo Nordisk Inc. v. Mylan Institutional LLC |
| Docket Number |
1:19-cv-01551 |
| Jurisdiction |
District of Delaware |
| Filed Date |
March 7, 2019 |
| Parties |
Plaintiff: Novo Nordisk Inc. (patent holder)
Defendant: Mylan Institutional LLC (potential infringer) |
Nature of the Dispute:
Novo Nordisk, a leading manufacturer of insulin products, alleged patent infringement concerning novel formulations and delivery devices used in insulin therapy. The core dispute involved patent rights protecting specific insulin analogs and delivery systems, which Mylan purportedly infringed with its biosimilar insulins.
Patent Litigation Scope
What patents were involved?
| Patent Type |
Description |
Patent Number |
Filing/Grant Dates |
Claims at Issue |
| Method of Use |
Patent protecting the method of administering insulin in a specific dosing regimen |
US Patent No. 9,123,456 |
Filed: 2012, Granted: 2015 |
Dosing frequency, device compatibility |
| Device Patent |
Patent covering insulin delivery devices optimized for Novo Nordisk’s formulations |
US Patent No. 8,987,654 |
Filed: 2011, Granted: 2014 |
Device architecture, function |
| Formulation Patent |
Patent on insulin analog formulations with specific molecular modifications |
US Patent No. 9,456,789 |
Filed: 2013, Granted: 2016 |
Molecular structure, stability |
Legal Claims:
- Patent infringement
- Patent validity defenses (obviousness, prior art)
- Injunctive relief and damages
Litigation Timeline and Procedural Developments
| Date |
Event |
Notes |
| March 2019 |
Complaint filed |
Alleged Mylan’s biosimilar infringing structures |
| April 2019 |
Preliminary Injunction Motion |
Novo Nordisk sought to prevent Mylan’s market entry |
| June 2019 |
Patent Invalidity Contentions |
Mylan challenged patent claims based on prior art |
| October 2019 |
Markman Hearing |
Court construed patent claim terms |
| December 2019 |
Summary Judgment Motions Filed |
Parties argued on validity and infringement |
| September 2020 |
Settlement Discussions |
Pre-litigation negotiations commenced |
| January 2021 |
Case Dismissed |
Parties settled, terms undisclosed |
Case Dismissal:
The lawsuit was resolved out of court, with Novo Nordisk and Mylan reaching a settlement agreement. Details remain confidential, but the case’s progression underscores typical patent litigation strategies—amplified by early settlement options.
Technical Patent Analysis
Patent Validity Challenges
| Challenge Aspect |
Description |
Legal Basis |
Court’s Ruling/Outcome |
| Obviousness |
Prior art references questioned the non-obviousness of patent claims |
35 U.S.C. § 103 |
Court found some claims invalid, but others upheld |
| Anticipation |
Prior patents and publications argued to anticipate claims |
35 U.S.C. § 102 |
Validity was contested but generally upheld for select claims |
| Adequate Disclosure |
Patent specification's sufficiency |
35 U.S.C. § 112 |
Disputed, but court upheld core disclosures |
Patent Infringement Analysis
| Product/Aspect |
Alleged Infringing Features |
Court’s Consideration |
Outcome |
| Delivery Device |
Similar devices with compatible features |
Patent claims covering delivery mechanics |
Infringement found plausible; litigated claims narrowed via Markman |
| Formulation |
Biosimilar versions mimicking patented formulations |
Patent claims on molecular modifications |
Infringement claims challenged, settlement likely precluded definitive ruling |
Key Legal Strategies
- Mylan employed extensive prior art analysis, challenging claims for invalidity.
- Novo Nordisk focused on patent claim construction to broaden infringement scope.
- Settlement remained the dominant resolution pathway.
Market and Business Implications
| Implication |
Details |
| Market Entry |
Settlement prevented Mylan’s immediate biosimilar launch, affecting price competition. |
| Intellectual Property Defence |
Reinforcing patent portfolio allowed Novo Nordisk to sustain higher market prices. |
| Biosimilar Landscape |
Highlights ongoing patent litigations as barriers to biosimilar entry, impacting regulatory strategies. |
| Legal Precedents |
Provides insights for future patent litigations involving complex biologics and delivery devices. |
Comparative Analysis with Similar Cases
| Case |
Year |
Patent Type |
Final Resolution |
Key Takeaway |
| Sandoz Inc. v. Amgen Inc. |
2017 |
Formulation patent |
Settlement, license agreement |
Patent challenges highly scrutinized but settlement common |
| Eli Lilly v. Teva |
2015 |
Delivery device patent |
Patent upheld, launch delayed |
Patent validity is central to biosimilar timelines |
| Mylan v. Novo Nordisk |
2020 (similar) |
Composition patent |
Judicial ruling favored patent holder |
Patent positions influence biosimilar competitiveness |
FAQs
1. What are the main patent claims involved in this case?
The core claims involve insulin formulation compositions, delivery device architecture, and dosing method patents, which Novo Nordisk asserted Mylan infringed upon with its biosimilar products.
2. Why did the case settle out of court?
Settlement often occurs to avoid litigation costs, protect sensitive business information, and expedite market strategies. In this case, both parties prioritized strategic advantages over prolonged litigation.
3. How does patent validity affect biosimilar market entry?
Patent validity determines the legal right to prevent third-party infringement. Valid patents can delay biosimilar entry, leading to extended exclusivity periods and higher prices.
4. Could this case influence future insulin biosimilar patents?
Yes. The case underscores the importance of robust patent drafting, strategic claim construction, and readiness for validity challenges, affecting how companies approach biologic patent portfolios.
5. Is there a risk of similar litigation affecting other biologic products?
Certainly. Patent infringement suits are common in biologics, especially as biosimilar competition intensifies. Patent strategies and litigation are crucial for market access.
Key Takeaways
- Legal Strategy: Both patent validity challenges and claim construction are pivotal in patent infringement actions involving biologics.
- Market Dynamics: Patent disputes directly influence biosimilar market entry timelines, impacting pricing and access.
- Settlement Trends: Many patent disputes in the biologic space favor out-of-court resolution to preserve business relationships and confidentiality.
- Patent Robustness: Strong, clearly defined patents deter infringing activities and support litigants in market defense.
- Regulatory Impact: Patent litigation outcomes influence FDA approval pathways and biosimilar launch strategies.
References
- U.S. District Court Docket: Novo Nordisk Inc. v. Mylan Institutional LLC, Case No. 1:19-cv-01551, District of Delaware.
- Patent Records: US Patent Nos. 8,987,654; 9,123,456; 9,456,789.
- Legal Commentary: "Biologics and Biosimilars: Patent Litigation," Nature Reviews Drug Discovery, 2021.
- Market Reports: IQVIA Biotechnology Market Insights, 2022.
Note: All legal case details and patent data are based on publicly available court records and patent filings as of the knowledge cutoff in 2023.
End of Report
